drugset / Trial / NCT06594640
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
Timeline
- Start
- 2024-05-30
- Primary completion
- 2026-06-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 16 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Prednisolone | Other / unclassified | 60 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.2 mg/m2 | — |